(anisoylated plasminogen streptokinase activator complex; APSAC) consists of a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme's active site.
Quantification of the benefit of earlier thrombolytic therapy: Five-year results of the Grampian Region Early Anistreplase
ISIS 3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase
and aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction.
The GREAT trial showed a substantially lower mortality at 1 year among patients randomized to prehospital anistreplase
(APSAC) at 10.4% compared with 21.6% among those treated in hospital (3).
Fibrinolytic agents include urokinase (Abbokinase[R]), tenecteplase (TNKase[R]), streptokinase (Streptase[R], Kabikinase[R]), alteplase (Cathflo[R], Activase[R], t-PA), reteplase (Retavase[R]), and anistreplase
The three agents in this category are anistreplase (Eminase) and streptokinase (Streptase), both rated C, and urokinase (Abbokinase).
No human pregnancy data are available for anistreplase.
As quality assurance issues with urokinase continued, the FDA suggested considering alteplase, streptokinase, anistreplase
, or reteplase as alternative thrombolytics, although there were few studies to support their use for catheter clearance (FDA, 2000, July 13).
The view now is that the effectiveness of anistreplase
is half that of what was originally claimed.
Long-term effects of intravenous anistreplase
in acute myocardial infarction: final report from the AIMS study.
GREAT (Grampian Region Early Anistreplase
Trial) calismasi nda hastane oncesi trombolitik tedavi hastane icindeki uygulamasi ile karsilastirildi (37).
Long term effect of intravenous anistreplase
in acute myocardial infarction: final report of the AIMS study.